Avicanna Inc., a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, announced that Avicanna has entered into a scientific and medical affairs collaboration agreement with Vectura Fertin Pharma.
Avicanna and Vectura Fertin Pharma are collaborating to establish a joint Scientific and Medical Affairs Committee focused on improving the understanding of medical cannabis access and applications in Canada. This committee will work closely with Canadian healthcare professionals to facilitate research studies and deliver evidence-based educational resources.
The collaboration will prioritize engagement with the Canadian medical community, patients, patient advocacy groups, and insurers to gain insights into the challenges associated with accessing medical cannabis. Additionally, the collaboration will leverage Avicanna’s medical cannabis platform, including Mymedi.ca with the aim of improving access and patient support.
Vectura Fertin Pharma is developing and commercializing a proprietary pipeline of differentiated products and brands in wellness and healthcare that address unmet patient and consumer needs.
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments.